Pourquoi, quand et comment doser les nouveaux anticoagulants oraux?

Translated title of the contribution: Why, when and how monitor new oral anticoagulants?

A. Tamigniau, J. Douxfils, J. B. Nicolas, B. Devalet, A. S. Larock, A. Spinewine, A. S. Dincq, S. Lessire, M. Gourdin, J. B. Watelet, V. Mathieux, C. Chatelain, J. M. Dogné, B. Chatelain, F. Mullier

Research output: Contribution to journalReview articlepeer-review

184 Downloads (Pure)

Abstract

Several direct oral anticoagulants (DOACs) are now widely used in the prevention and treatment of thromboembolic events. Unlike vitamin K antagonists, DOACs exhibit predictable pharmacokinetics and pharmacodynamics. DOACs are to be administered at fixed doses without routine coagulation monitoring. However, in some patient populations or specific clinical circumstances, measurement of drug exposure may be useful, such as in suspected overdose, in patients with a haemorrhagic or thromboembolic event during treatment with an anticoagulant, in those with acute renal failure, or in patients who require urgent surgery. This article provides practical guidance on laboratory testing of DOACs in routine practice and summarizes the influence of DOACs on commonly used coagulation assays.

Translated title of the contributionWhy, when and how monitor new oral anticoagulants?
Original languageFrench
Pages (from-to)326-333
Number of pages8
JournalRevue médicale suisse
Volume10
Issue number416
Publication statusPublished - 5 Feb 2014

Keywords

  • Administration, Oral
  • Anticoagulants
  • Blood Coagulation Tests
  • Drug Monitoring
  • Humans
  • Kidney Failure, Chronic

Fingerprint Dive into the research topics of 'Why, when and how monitor new oral anticoagulants?'. Together they form a unique fingerprint.

Cite this